FDA Approves Ketamine Product, KETARx, for Surgical Pain Management
MONDAY, Aug. 18, 2025 -- The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.
Ketamine is the only psychedelic or psychedelic-adjacent drug on the World Health Organization Essential Medicines List, with its global market projected to grow from $750 million to $3.42 billion by 2034.
PharmaTher, which developed KETARx, believes there is a promising outlook for the ketamine market and that the FDA approval provides a strong foundation for expanding the development of ketamine across diverse therapeutic areas. These areas include depression, neurological disorders (Parkinson disease, amyotrophic lateral sclerosis), and rare or chronic pain conditions.
"Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for PharmaTher is a testament to years of dedicated development, signaling a new era of growth," Fabio Chianelli, founder and CEO of PharmaTher, said in a statement. "We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders."
Approval of KETARx was granted to PharmaTher.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Self-Medicating With Weed Might Make Things Worse
FRIDAY, Sept. 5, 2025 — Folks who start using weed to cope with anxiety, depression or pain might end up with a worse mental state than before, a new study says. People...
Most Pain Patients Quit Medical Weed Within A Year, Study Says
MONDAY, Aug. 25, 2025 — More than half of people prescribed medical weed for chronic muscle or joint pain quit using it within a year, a new small-scale study says. About...
Artery-Blocking Procedure Relieves Knee Arthritis Pain
FRIDAY, Aug. 22, 2025 — Wear-and-tear knee arthritis might be made less painful by a surgical procedure that limits blood flow to the joint, a new pilot study says. As a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.